Radiation Therapy for B-Cell Lymphoma

Palo Alto (17 mi)

Overseen byChirayu Patel, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: N/A

Recruiting

Sponsor: Massachusetts General Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This is a novel administration schedule and we're looking to see how this schedule impacts side effects participants may experience, the time spent receiving radiation therapy, how much radiation therapy participants can receive, and how effective this new schedule is.

Eligibility Criteria

This trial is for adults over 18 with B-cell Lymphoma that's come back or hasn't responded to treatment, and who are set to undergo CAR T-cell therapy. They should be able to lay still for the duration of radiation sessions and not have conditions interfering with the study.

Treatment Details

The study tests a new weekly schedule of Adaptive Bridging Radiation Therapy (ABRT) over five weeks before CAR T-cell therapy in patients with relapsed/refractory B-cell Lymphoma, aiming to improve side effects, time, cost, and effectiveness.

1Treatment groups

Experimental Treatment

Group I: 5-5-5 Adaptive Bridging Radiation Therapy (ABRT)Experimental Treatment1 Intervention

5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion